RPID RPID
Company Profile ↓Company Overview
RPID (RPID) is a publicly traded company listed on with a market capitalization of $93.83M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 20.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $33.59M (+19.7% YoY); net profit $-47.12M.
- Trailing 12 Months Year-on-year growth — revenue +19.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.22% |
| 1 Year: | 19.74% |
Stock Price Performance
| 1 Year: | -36.25% |
| 6 Months: | -51.49% |
| 3 Months: | -14.92% |
| 1 Month: | +21.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)58.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.2% over 5 years.
CONS
- Trading 54.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.59M | 5.25M | 5.00M | 6.13M | 6.90M | 4.16M | 3.86M | 4.74M | 5.04M | 5.00M | 6.14M | 5.61M | 6.62M | 7.60M | 7.21M | 7.26M | 7.84M | 11.28M | 8.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.80M | 6.99M | 7.14M | 11.61M | 7.63M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 404.00K | 275.00K | 696.00K | -328.00K | 371.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.06M | 12.42M | 12.07M | 11.88M | 14.22M |
| Operating Income | - | -6.01M | -7.58M | -9.69M | -10.86M | -12.12M | -15.00M | -14.07M | -16.89M | -14.87M | -15.05M | -14.45M | -14.27M | -13.38M | -12.04M | -11.66M | -12.15M | -11.37M | -12.21M | -13.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.40M | -11.34M | -10.30M | -11.02M | -12.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00K | - | 393.00K | 673.00K | 639.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.26M | -11.85M | -11.50M | -12.48M | -14.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00K | 11.00K | 8.00K | 14.00K | 8.00K |
| Net Income | -8.01M | -9.27M | -8.46M | -22.10M | -11.83M | -24.99M | -14.93M | -13.09M | -16.34M | -13.89M | -14.02M | -13.39M | -13.32M | -12.58M | -11.32M | -11.26M | -11.86M | -11.51M | -12.50M | -14.28M |
| Diluted EPS | - | -31.93 | -30.08 | -37.89 | -20.01 | -0.71 | -0.35 | -0.31 | -0.38 | -0.32 | -0.33 | -0.31 | -0.31 | -0.29 | -0.26 | -0.26 | -0.27 | -0.26 | -0.28 | -0.31 |
| R&D Expense | - | 1.24M | 2.22M | 2.15M | 2.34M | 2.44M | 3.52M | 2.96M | 2.97M | 3.15M | 3.23M | 3.12M | 3.84M | 3.74M | 3.61M | 3.62M | 3.23M | 3.53M | - | 3.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 16.08M | - | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | - | - | 25.67M | 28.00M | 28.16M | 32.54M |
| Gross Profit | - | - | -8.54M | -5.49M | -109.00K | 1.05M |
| Operating Expenses | - | - | 54.68M | 51.08M | 49.81M | 48.44M |
| Operating Income | -30.54M | - | -63.22M | -56.56M | -49.92M | -47.39M |
| EBITDA | - | - | -60.38M | -53.46M | -43.47M | -42.74M |
| Interest Expense | - | 2.65M | - | - | 40.00K | 1.09M |
| Pretax Income | - | - | -61.38M | -52.44M | -46.87M | -47.08M |
| Tax Provision | - | - | -576.00K | 31.00K | 22.00K | 40.00K |
| Net Income | -37.08M | - | -60.81M | -52.47M | -46.89M | -47.12M |
| Diluted EPS | -126.11 | - | -1.43 | -1.22 | -1.08 | -1.05 |
| R&D Expense | 6.53M | 9.78M | 12.87M | 12.82M | 14.60M | 13.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 70.00M | - | 190.65M | 143.45M | 98.17M | 74.85M |
| Current Assets | - | - | - | 138.58M | 120.42M | 80.92M | 61.17M |
| Cash & Equivalents | - | 30.08M | - | 27.06M | 24.29M | 16.91M | 20.03M |
| Inventory | - | - | - | 21.19M | 19.96M | 20.20M | 17.59M |
| Receivables | - | - | - | 5.37M | 5.53M | 7.52M | 3.13M |
| Total Liabilities | - | 45.18M | - | 26.48M | 25.46M | 22.82M | 41.65M |
| Current Liabilities | - | 15.54M | - | 19.05M | 18.99M | 17.57M | 18.49M |
| Long Term Debt | - | 24.81M | - | - | - | - | 18.90M |
| Total Debt | - | - | - | 7.97M | 7.35M | 6.17M | 23.87M |
| Total Equity | -82.58M | -127.01M | - | 164.17M | 117.99M | 75.35M | 33.21M |
| Shares Outstanding | - | - | - | 42.09M | 42.41M | 43.04M | 44.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.00M | - | -58.55M | -45.08M | -44.15M | -31.06M |
| Investing Cash Flow | -15.67M | - | -93.47M | 42.15M | 36.66M | 14.33M |
| Financing Cash Flow | 64.23M | - | 693.00K | 149.00K | 203.00K | 19.77M |
| Capital Expenditure | -690.00K | - | -6.74M | -1.84M | -1.36M | -850.00K |
| Free Cash Flow | -31.69M | - | -65.29M | -46.93M | -45.52M | -31.91M |
| Net Change in Cash | - | - | -151.32M | -2.78M | -7.29M | 3.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | -49.8% | -24.4% | -0.4% | 3.1% |
| Operating Margin % | -190.0% | - | -369.0% | -251.2% | -178.0% | -141.1% |
| Net Margin % | -230.6% | - | -354.9% | -233.0% | -167.2% | -140.3% |
| ROE % | 29.2% | - | -37.0% | -44.5% | -62.2% | -141.9% |
| ROCE % | -56.1% | - | -36.8% | -45.4% | -61.9% | -84.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RPID
Rapid Micro Biosystems New Hire Receives 90,000 RSUs and Option - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQbXpqa2NIZnhGUVhPb3F4NFpHSU81bEVzWWMySVlQTjJwR0dxdnVyVmxMSGc1LUdDV3lPU1F6U2lnMm44LWpfWXdZSUFCeEtYNHNMSkthWHlWaXlJVl9QVUd4WnVtVFo0UmR2cHNaMTVuRTlDcjZma0s0a2REM05xY2h3UkFjRDQ3SWJneH…
RPID|Rapid Micro Biosystems Inc|Price:2.070|Chg%:-0.050 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBRcF9EUG1uVlJMTmMtRmYxUnllek1NV2dkUFdadnlxM1F4dHp6bXdSUlZ2ZTZlcmkwZmQwcTdpUDRMYkFhd2xyWU83N0xZdzZmcWZ0RUZVNWN2SEYwNG16RnJMZ1ltT3ZOd1pDRERR?oc=5" target="_blank">RPID|Rapid Micro Bi…
White Brook Capital Shared Insights on Rapid Micro Biosystems (RPID) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOcmlnNlFUU1ZwWWtPdEQ2SVhrXzBPcVZFQ1NpYjE2VEkxZ1lfYjgwU3JWQURtQ0thSnV0SC1haGF4WFRGaWg0d095aEV5ODNyM3lLOHFiMEhESXFIMmx0cElUV1VwSU1nLWpLeUc4ZkttM280NUhYTFBVRGNMZ0FRMHh5LVlJXy1tdXFBTj…
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPVHBLd1FBMk5HV1k2SGJ0eFBtaDdZSlRiam9zOFcxeTYxYXJzejBjUzg0OUVFc24ySXA5VzR4LXV3NGt0d2c2VEpxNU5LVnl3anJuMERWUXRZRnY4TUFJR3BidDQzY0pRLWxiYzNiUmhZbzJoNDZmaU1kTWd4d1paR0FUM0k1eng5aE5zRD…
RPID Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1mNjZyV28xUElvZUh3ODJ1UmpaVEhnaVdBRUt2WEdRZEJyb2lhVWZfdHZUUkN5aTVuc3B2c0I3SDFBOHhPRHc1Z3RSeVRrRzFXbnVJOWpSaDNyTVNjcWlZTF9vd0g0bHd5ZkpybkJMemNPckk5aW1wTndn?oc=5" target="_blank">RPI…
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPQUdBeG9NTXFWQ09EMmQwM01zT0piUklQUjAxTWhGTG0zdWhGUnp4TEx5MW5WdWtOSG5DcFZhQ1l2bi1wTDNZUE1JLVlMNXZlc044c2RyRmdTOXRFMHp2UjlNTDA2Sno3dlhYSXo5eTRwMEpic3dBU3E2bHlWeVI5c1VLNkkwa0VZQlgwSX…
RPID — Frequently Asked Questions
What is the current share price of RPID?
As of 2026-08-05 17:25 PDT, RPID trades at $2.11 on NASDAQ/NYSE. Its 52-week range is $1.66 to $4.68.
What is the market capitalisation of RPID?
RPID has a market capitalisation of $93.83M on NASDAQ/NYSE.
What is the P/E ratio of RPID?
RPID trades at a trailing price-to-earnings (P/E) ratio of -2.01. Its price-to-book (P/B) ratio is 2.83.
What is the return on equity (ROE) of RPID?
RPID has a return on equity (ROE) of -141.91%. Its return on capital employed (ROCE) is -84.08%.
Is RPID a good stock to buy?
This page provides a data-driven analysis of RPID, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.